TuisCYCCP • NASDAQ
add
Cyclacel Pharmaceuticals Inc Conv. Pref. Shrs
Vorige sluiting
$7,50
Dagwisseling
$7,20 - $8,58
Jaarwisseling
$5,20 - $22,20
Markkapitalisasie
2,44 m USD
Gemiddelde volume
4,55 k
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 10,00 k | -37,50% |
Bedryfskoste | 2,19 m | -68,12% |
Netto inkomste | -1,96 m | 67,56% |
Netto winsgrens | -19,57 k | 48,09% |
Wins per aandeel | -0,18 | 97,55% |
EBITDA | -2,18 m | 68,18% |
Effektiewe belastingkoers | 9,69% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,98 m | -49,83% |
Totale bates | 5,38 m | -56,94% |
Totale aanspreeklikheid | 6,35 m | -22,55% |
Totale ekwiteit | -970,00 k | — |
Uitstaande aandele | 6,29 m | — |
Prys om te bespreek | -16,67 | — |
Opbrengs op bates | -80,21% | — |
Opbrengs op kapitaal | -32 014,71% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -1,96 m | 67,56% |
Kontant van bedrywe | -3,07 m | 24,01% |
Kontant van beleggings | — | — |
Kontant van finansiering | -1,00 k | 98,00% |
Netto kontantverandering | -3,02 m | 28,48% |
Beskikbare kontantvloei | -2,31 m | 8,20% |
Meer oor
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow. Wikipedia
Gestig
13 Aug. 1996
Webwerf
Werknemers
12
